Stockreport

Annexon Investor Day: ANX007 Targets C1q in Dry AMD GA as Phase III Readout Nears Q4 [Yahoo! Finance]

Annexon, Inc. - common stock  (ANNX) 
PDF and visual function, a strategy Annexon argues is distinct from approved downstream C3/C5 inhibitors that target lesion/RPE atrophy. In the 270-patient Phase II ARCHER [Read more]